Article

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World Study

2025-07-31

Abstract excerpt

<title>Abstract</title> <p> Racial and ethnic minorities have been underrepresented in pivotal trials of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), limiting the generalizability of findings. This multicenter retrospective study evaluated real-world outcomes in minority patients (MP) versus White patients (WP) treated with cilta-cel or ide-cel across five U.S. centers between May...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2770c91e-0b71-5957-9cbe-a0ee0a02a930
DOI: 10.21203/rs.3.rs-7208369/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudyDOI 10.21203/rs.3.rs-7208369/v1Read

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read

Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responsesSemantic proximity Read

Single-Cell Analysis Reveals Ide-cel and Cilta-cel Characteristics That Influence EfficacySemantic proximity Read

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity Read

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read

A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myelomaSemantic proximity Read

CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy.Semantic proximity Read

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read

Next-Generation Chimeric Antigen Receptor T-cellsSemantic proximity Read